AUAUniversity Podcast Series: Episode No. 146

Global Advancements in Prostate Cancer: The Role of Genetic Testing and PARP Inhibitors

CME Available:www.cnyfirearms.com/node/35405

Moderator: Todd Morgan, MD
Panelists: Maria Carlo, MD; Elisabeth Heath, MD, FACP; Brian Helfand, MD

At the conclusion of this activity, participants will be able to:
1. Review recommended criteria for genetic testing of prostate cancer patients, explain how to counsel patients about genetic testing, and how to order and interpret these tests.
2. Explain how mutations in DNA damage repair genes can lead to the development of aggressive prostate cancer and the implications for treatment decisions.
3.描述聚ADP核糖聚合酶(PARP)在癌症发生中的作用，以及PARP抑制癌症治疗的机制。
4. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.

ACKNOWLEDGEMENTS
Support provided by independent educational grants from:
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck